{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:23Z","timestamp":1781835143276,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T00:00:00Z","timestamp":1456444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ajo.2016.02.026","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T06:14:42Z","timestamp":1456985682000},"page":"188-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%\/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1695-4322","authenticated-orcid":false,"given":"Robert M.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McMenemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Hubatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Realini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2016.02.026_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1442-9071.2012.02773.x","article-title":"Definition of glaucoma: clinical and experimental concepts","volume":"40","author":"Casson","year":"2012","journal-title":"Clin Experiment Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2016.02.026_bib2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00002512-200825090-00002","article-title":"Pharmacological management of primary open-angle glaucoma: second-line options and beyond","volume":"25","author":"Webers","year":"2008","journal-title":"Drugs Aging"},{"issue":"Suppl1","key":"10.1016\/j.ajo.2016.02.026_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.survophthal.2008.08.006","article-title":"Risk factors for glaucoma onset and progression","volume":"53","author":"Coleman","year":"2008","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2016.02.026_bib4","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Early Manifest Glaucoma Trial G. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2016.02.026_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2016.02.026_bib6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ophtha.2004.11.030","article-title":"Results of the European Glaucoma Prevention Study","volume":"112","author":"Miglior","year":"2005","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2016.02.026_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","article-title":"Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2016.02.026_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00061198-199804000-00006","article-title":"Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States","volume":"7","author":"Kobelt-Nguyen","year":"1998","journal-title":"J Glaucoma"},{"issue":"5","key":"10.1016\/j.ajo.2016.02.026_bib9","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ophtha.2009.10.038","article-title":"Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma","volume":"117","author":"Rees","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2016.02.026_bib10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ophtha.2004.12.026","article-title":"Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?","volume":"112","author":"Robin","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2016.02.026_bib11","first-page":"1","article-title":"Considerations in glaucoma therapy: fixed combinations versus their component medications","volume":"4","author":"Higginbotham","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2016.02.026_bib12","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamaophthalmol.2013.188","article-title":"Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%","volume":"131","author":"Katz","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2016.02.026_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/jop.2012.0235","article-title":"Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%\/brimonidine 0.2%","volume":"29","author":"Nguyen","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ajo.2016.02.026_bib14","unstructured":"European Glaucoma Society. Terminology and Guidelines for Glaucoma. DOGMA Srl. Available at http:\/\/www.eugs.org\/eng\/EGS_guidelines.asp. Accessed December 21, 2015."},{"key":"10.1016\/j.ajo.2016.02.026_bib15","series-title":"Preferred Practice Pattern\u00ae Guidelines. Primary Open-Angle Glaucoma","author":"American Academy of Ophthalmology Glaucoma Panel","year":"2010"},{"issue":"9","key":"10.1016\/j.ajo.2016.02.026_bib16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.ophtha.2009.03.050","article-title":"Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs","volume":"116","author":"Bournias","year":"2009","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2016.02.026_bib17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ophtha.2007.03.012","article-title":"Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%","volume":"114","author":"Feldman","year":"2007","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2016.02.026_bib18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00417-011-1650-8","article-title":"Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension","volume":"249","author":"Pfeiffer","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2016.02.026_bib19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clinthera.2006.04.007","article-title":"A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Reis","year":"2006","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.ajo.2016.02.026_bib20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1089\/jop.2012.0195","article-title":"Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide\/timolol or brimonidine\/timolol fixed-combination adjunctive to travoprost therapy","volume":"29","author":"Konstas","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ajo.2016.02.026_bib21","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.ophtha.2008.04.011","article-title":"Intraocular pressure-lowering efficacy of brinzolamide 1%\/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%","volume":"115","author":"Kaback","year":"2008","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2016.02.026_bib22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","article-title":"Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension","volume":"132","author":"Netland","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2016.02.026_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2016.02.026_bib24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.ijg.0000212274.50229.c6","article-title":"Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy","volume":"16","author":"Lewis","year":"2007","journal-title":"J Glaucoma"},{"issue":"12","key":"10.1016\/j.ajo.2016.02.026_bib25","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.ophtha.2014.06.022","article-title":"Twice-daily brinzolamide\/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension","volume":"121","author":"Aung","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2016.02.026_bib26","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2147\/OPTH.S46881","article-title":"Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1%\u00a0+ brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension","volume":"7","author":"Whitson","year":"2013","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2016.02.026_bib27","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1167\/iovs.02-0666","article-title":"Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes","volume":"44","author":"Liu","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ajo.2016.02.026_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archopht.121.4.453","article-title":"The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension","volume":"121","author":"Orzalesi","year":"2003","journal-title":"Arch Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939416300769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939416300769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:32:34Z","timestamp":1757597554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939416300769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":28,"alternative-id":["S0002939416300769"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2016.02.026","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%\/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2016.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}